Abstract 30P
Background
One of the risk factors to develop colorectal cancer (CRC), which is one of the deadliest types of cancer, is inflammation. Among the factors involved in the inflammatory response, prostaglandins (PGs) seem to play an important role. The tumor microenvironment (TME) influences the development of the tumor and within the TME, cancer associated fibroblasts (CAFs) represent the major compartment. Despite the importance of the TME, there is limited evidence on the secretome-dependent communication of CRC cells with CAFs and myeloid cells with respect to PG signaling. In this project we mainly focus on PGE2 and PGF2α, that we have previously found are secreted by CAFs.
Methods
By using in vitro 3D cocultures secreted molecules induced by increased or decreased PGE2 and PGF2α expression were identified. The levels of both PGs were measured by ELISA, whereas the expression of the production enzymes was analyzed by Western Blot. Phenotypic analysis and functional assays were carried out using siRNA or specific inhibitors to analyze the effect on angiogenesis and contractility of CAFs, their proliferation, motility, and apoptosis levels. Finally, preliminary in vivo experiments were performed and, additionally, paraffin tissue sections from patient-derived xenografts (PDX) models were stained to prove the stroma expression of the PGs specific synthases.
Results
We demonstrate that a combination of proinflammatory cytokines can increase the expression of COX-2 and mPGES-1 while IL-4 decreases it. Knocking down the specific synthases of PGE2 and PGF2α in the CAFs also leads to a decrease in their proliferation, contractiliy, motility and angiogenesis capacity, but did not induce apoptosis. In vivo, knocking down of the PGs specific synthases seems to lead to a worse survival capacity, and some of these enzymes seem to be only expressed in the stromal cells of PDX models.
Conclusions
More information about the link between cancer and its TME would help us to achieve a higher degree of accuracy in the development of potential future therapies. Here we have proved that the action of PGs, especially PGF2α and PGE2, is involved in tumor development in 2D and 3D suggesting a possible therapeutic target.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Marie Skłodowska-Curie Actions - PhD Research Fellowship. European Commission (Horizon 2020).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09